巴曲酶联合针刺疗法治疗难治性突发性耳聋的临床疗效OACSTPCD

Objective To observe the clinical efficacy of batroxobin in treating refractory sudden sensorineural hearing loss(SSNHL)and to investigate factors influencing the treatment outcomes of SSNHL patients.Methods A ret-rospective analysis was conducted on 82 patients(106 ears)with SSNHL admitted to the Department of Otorhinolaryngoloy at Foshan Hospital of Traditional Chinese Medicine from July 2022 to April 2024.Of these,34 patients(43 ears)who underwent secondary treatment were classified as the refractory SSNHL group,with the remaining patients serving as the control group.Both groups received batroxobin injection,standard acupuncture,neurotrophic agents,and microcirculation-improving treatments.Clinical efficacy,changes in pure tone audiometry thresholds,Tinnitus handicap inventory(THI)scores,and hematologic parameters were observed and compared before and after treatment.Results The overall treat-ment effectiveness rate in the refractory SSNHL group(30.23％)was lower than that in the control group(39.68％).For patients with severe to profound hearing loss in the refractory SSNHL group,the mean speech frequency hearing threshold was reduced from(84.36±11.63)dBHL before treatment to(65.43±10.23)dBHL after treatment.Both groups showed statistically significant improvements in THI scores before and after treatment(P＜0.01).Duration of ill-ness,fibrinogen level,neutrophil-to-lymphocyte ratio(NLR),and lymphocyte-to-monocyte ratio(LMR)were identified as independent prognostic risk factors(P＜0.05).Conclusion Although treatment outcomes in refractory SSNHL patients are generally suboptimal,batroxobin combined with acupuncture provides significant clinical benefits for improving hearing and tinnitus symptoms in these patients.